Presentation

Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients

International Gynecologic Cancer Society (IGCS) Annual Global Meeting

2025

Presentation

ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor

European Society for Medical Oncology (ESMO) Congress

2025

Poster

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

European Society for Medical Oncology (ESMO) Congress

2025

Poster

Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)

European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress

2025

Presentation

Phase 3 Results of Relacorilant + Nab-Paclitaxel v Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer (ROSELLA): Secondary Endpoints

European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress

2025

Presentation

ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer

American Society of Clinical Oncology (ASCO) Annual Meeting

2025